Article
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Strong Bullish
100.0
−100 Bearish
0
+100 Bullish
Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Sentiment Signal
Strong Bullish
100.0
−100Neutral+100
More Like This